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Abstract
Epithelial cell adhesion molecule EpCAM is a transmembrane glycoprotein, which is highly and frequently expressed in
carcinomas and (cancer-)stem cells, and which plays an important role in the regulation of stem cell pluripotency. We show
here that murine EpCAM (mEpCAM) is subject to regulated intramembrane proteolysis in various cells including embryonic
stem cells and teratocarcinomas. As shown with ectopically expressed EpCAM variants, cleavages occur at a-, b-, c-, and e-
sites to generate soluble ectodomains, soluble Ab-like-, and intracellular fragments termed mEpEX, mEp-b, and mEpICD,
respectively. Proteolytic sites in the extracellular part of mEpCAM were mapped using mass spectrometry and represent
cleavages at the a- and b-sites by metalloproteases and the b-secretase BACE1, respectively. Resulting C-terminal fragments
(CTF) are further processed to soluble Ab-like fragments mEp-b and cytoplasmic mEpICD variants by the g-secretase
complex. Noteworthy, cytoplasmic mEpICD fragments were subject to efficient degradation in a proteasome-dependent
manner. In addition the c-secretase complex dependent cleavage of EpCAM CTF liberates different EpICDs with different
stabilities towards proteasomal degradation. Generation of CTF and EpICD fragments and the degradation of hEpICD via the
proteasome were similarly demonstrated for the human EpCAM ortholog. Additional EpCAM orthologs have been
unequivocally identified in silico in 52 species. Sequence comparisons across species disclosed highest homology of BACE1
cleavage sites and in presenilin-dependent c-cleavage sites, whereas strongest heterogeneity was observed in
metalloprotease cleavage sites. In summary, EpCAM is a highly conserved protein present in fishes, amphibians, reptiles,
birds, marsupials, and placental mammals, and is subject to shedding, c-secretase-dependent regulated intramembrane
proteolysis, and proteasome-mediated degradation.
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Introduction
Regulated intramembrane proteolysis (RIP) is an important
means of regulation for a growing number of transmembrane
proteins [1,2]. Through the function of various sheddases and the
multiprotein c-secretase complex comprised of minimally pre-
senilin, APH-1, PEN-2, and nicastrin, RIP substrates are
sequentially cleaved to release an extracellular ectodomain and
an intracellular domain (ICD). Amyloid precursor protein (APP) is
a prototype RIP substrate that was analysed in great detail owing
to its central function in the pathophysiology of Alzheimer’s
disease. Apart from an ectodomain and an ICD, processing of
APP additionally results in the formation of a small peptides
corresponding to the remainder of the extracellular domain after
shedding and parts of the transmembrane domain [3]. One of
these peptides, termed b-amyloid (Ab), can misfold and form
plaques in brains of Alzheimer’s disease patients. Numerous
proteins have now been described to follow the scheme of RIP
similarly to APP, i.e. sequential cleavages by a-secretases of the
ADAM type, b-secretases such as BACE1 [4], and the c-secretase
complex. RIP substrates include Notch receptors [5], CD44 [6],
L1 [7,8], ERBB family members [9], and the tumour-associated
antigen EpCAM [10], amongst others (for review see [1]). The
biological roles of RIP are several-fold and include the generation
of soluble extracellular domains with ligand activity, formation of
Ab-like peptides, release and nuclear translocation of ICDs with
transcriptional capacity, and protein degradation [1,11].
The tumour-associated antigen EpCAM (Epithelial Cell Adhe-
sion Molecule) is a single transmembrane protein, which is highly
and frequently expressed in human and rodent carcinomas, tissue
progenitors, embryonic and adult stem cells [12,13]. The first
described function of EpCAM was name-giving and referred to its
ability to provide epithelial cells with a weak cell adhesion through
homophilic interactions of EpCAM molecules [14]. The second
function of EpCAM relates to the regulation of proliferation and
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was in the first place described as a correlation of the expression of
EpCAM with areas of proliferation in tumours [15,16]. The
involvement of EpCAM in the regulation of proliferation was in
the meantime studied in more detail and reported for several
conditions including tumours [17,18,19,20]. Expression of Ep-
CAM in otherwise negative cells induced the expression of the
oncogene MYC and fostered proliferation [21]. Oppositely, the
reduction of EpCAM expression correlated with diminished
proliferation [17], along with a decreased expression of the cell
cycle regulator cyclin D1 [22]. In patients, strong expression of
EpCAM mostly correlated with a diminished overall survival
[19,23,24], whereas some entities such as gastric cancers displayed
the opposite correlation, with increased survival in the presence of
high-level EpCAM expression [25]. Interestingly, even within one
cancer entity, correlation of EpCAM expression with overall
survival may vary across intrinsic subtypes. For example, EpCAM
expression correlated with an unfavourable outcome in patients
suffering from basal-like and luminal breast cancer subtypes, while
high-level EpCAM expression was associated with enhanced
overall survival in the HER2 subtype [26].
The mode of action of human EpCAM in the regulation of
proliferation is dependent on RIP and the formation of hEpICD,
the intracellular domain of EpCAM [10]. Human EpICD,
comparably to Notch-ICD, translocates into the nucleus of
carcinoma cells in combination with the adaptor protein FHL2
and b-catenin to bind together with LEF1 to consensus sequences
within promoters of target genes including cyclin D1 [22].
Similarly to Notch-ICD and ICDs of other RIP substrates
[27,28,29], the detection of endogeneous hEpICD was compli-
cated and required very large amounts of protein lysate in
combination with immunoprecipitation, and suggested substantial
unstableness of this protein fragment [10]. Additionally to
proliferation, EpCAM cleavage apparently plays a role in the
maintenance of the pluripotent state of human embryonic stem
cells and the regulation of differentiation, where EpICD binds to
the promoters of pluripotency genes such as MYC, NANOG,
POU5F1 (Oct3/4), SOX2, and KLF4 [30]. Consequently, over-
expression of both, full-length EpCAM or EpICD, significantly
enhanced reprogramming efficiency in mouse embryonic fibro-
blasts [31]. Comparably, the murine ortholog of EpCAM
(mEpCAM), which shares high sequence homology with the
human counterpart, was reported to be relevant to the mainte-
nance of a pluripotent state of embryonic stem cells [32]. High-
level expression of mEpCAM was also a hallmark of murine
epithelial stem cells of the lung, which were additionally
characterised by the expression of CD49f and CD104, low
expression of CD24, and were capable of generating airway,
alveolar and mixed lung epithelia [33]. Thus, mEpCAM appears
to be involved in the regulation of the differentiation state in
murine cells, too.
To the best of our knowledge, regulated intramembrane
proteolysis of EpCAM was formally demonstrated solely for the
case of the human protein so far. Here, we investigated the
potential cleavage of mEpCAM and describe for the first time a-,
b-, and c-secretase proteolytic sites along with the generation of
soluble EpEX, Ab-like fragments, and different variants of
mEpICD, which are highly prone to degradation by the
proteasome. Comparison of EpCAM sequences across species
disclosed a high homology within b- and c-cleavage sites, and
stronger heterogeneity within a- and e-cleavage sites. We further
demonstrate that human EpICD, similarly to mEpICD, is a target
of proteasomal degradation. Thus, regulated intramembrane
proteolysis and proteasomal degradation appear as a general
theme of regulation of the function and stability of EpCAM within
vertebrates.
Results
Murine EpCAM is Subject to Regulated Intramembrane
Proteolysis
Regulated intramembrane proteolysis (RIP) of human EpCAM
was reported in carcinoma and HEK293 cells [10]. Similarly to
these previous reports, the murine ortholog of EpCAM (mEp-
CAM) was fused to yellow fluorescent protein (YFP) to increase the
size of cleavage products and to facilitate their detection (see
schematic view in Figure 1A). Cleavage and functionality of
hEpCAM-YFP/hEpICD-YFP were demonstrated in earlier ap-
proaches in vitro and in vivo [10]. Cleavage was investigated in
isolated membranes of stable HEK293 transfectants expressing
full-length mEpCAM-YFP as described before [34]. Isolated
membranes of these cells were incubated for 0 h to 22 h in a time
course at 37uC to allow for cleavage to occur. Thereafter,
membranous and soluble fractions were harvested separately via
differential centrifugation and the presence of cleaved variants of
mEpCAM determined in immunoblot experiments with mE-
pICD- and YFP-specific antibodies. Three distinct proteins were
detected with mEpICD- and YFP-specific antibodies in particulate
fractions of membrane-based assays (Figure 1B). Apparent
molecular masses were calculated using the Chemidoc XRS+
imaging system and corresponded to the predicted molecular mass
for mEpCAM-YFP (predicted: 62.55 kDa; apparent: 66.7 kDa),
CTF-YFP (predicted: 34.5–37 kDa; apparent: 34.9 kDa), and
mEpICD-YFP (predicted: 31 kDa; apparent: 29.9 kDa). These
molecular weights refer to fusions with YFP, hence 25 kDa must
be subtracted to determine actual EpCAM fragment sizes. Only
small amounts of the C-terminal fragment mCTF-YFP were
present at the initial time point, which might reflect the overall
status of mEpCAM cleavage at the time of membrane isolation. At
this time point, a major mCTF fragment with an approximate
molecular weight of 34.9 kDa represented the dominant mCTF
band. Two additional bands of weaker intensity and with
molecular weights of 37 kDa and 40 kDa were detected using
mEpICD-specific antibodies (Figure 1B). Upon time, these two
proteins disappeared and after 2.5 h, the level of the 34.9 kDa
mCTF-YFP strongly increased and remained stable over the
observation time of 22 h (Figure 1B). At later time points, we
observed the appearance of a smaller mEpICD-reactive protein,
which corresponded to mEpICD-YFP, in comparably small
amounts (Figure 1B). All three major protein species were
identified with mEpICD and YFP-specific antibodies. In super-
natants of membrane assays, two mEpICD and YFP-reactive
proteins were detected, which corresponded to the 34.9 kDa
mCTF-YFP and mEpICD-YFP (Figure 1C). The ratio of mCTF-
YFP to mEpICD-YFP was inversed in supernatants versus pellets,
in line with the notion that mEpICD is release from membrane-
bound mCTF-YFP as a soluble protein. Residual levels of
mEpCAM-YFP and mCTF-YFP occasionally seen in supernatants
and of mEpICD-YFP in pellets might represent minor cross-
contaminations of subcellular fractions.
Next, we analysed the potential cleavage of mEpCAM-YFP in
murine embryonic stem cells (ESCs; E14TG2a) and in teratocar-
cinoma cells (mF9). Stable transfectants were subjected to
membrane assays and resulting YFP-reactive proteins were
detected in immunoblot experiments at late time points to ensure
quantitative cleavage. In both cell lines, generation of mEpICD-
YFP was observed after 24 h and was most prominent in mF9 cells
(Figure 1D). Additionally, mCTF-YFP was detected in mF9 cells
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along with a protein band corresponding to YFP only, probably
due to degradation (labelled * in Figure 1D). Inhibition of the c-
secretase complex, which was reported to be involved in cleavage
of human EpCAM [10], with the synthetic inhibitor DAPT
resulted in the accumulation of mCTF-YFP and the lack of
detectable mEpICD in both cell lines (Figure 1D). Thus,
mEpCAM is subject to c-secretase-dependent RIP.
Determination of Cleavage Sites of Sheddases within
EpCAM
In the following, we intended to identify cleavage sites within
mEpCAM at the amino acid level using mass spectrometry
approaches. RIP is a sequential process, which involves the initial
cleavage of proteins by sheddase(s) in the extracellular domain and
intramembrane proteases. The extracellular domain of mEpCAM
is strongly glycosylated, which would hinder proper analysis of the
resulting peptides in mass spectrometry. For this reason, similarly
to a previous study [35] two peptide motifs (tags) were
incorporated 42 amino acids away from the predicted transmem-
brane domain within the extracellular domain of mEpCAM in
order to generate mEpCAM-TF. Incorporation of these tags did
not impair the cleavage of substrates such as amyloid precursor-
like protein 2 (APLP2) and were therefore used in the present
study [35]. The first motif represents a consensus site for the
tobacco etch virus (TEV) protease, while the second encodes the
FLAG tag. After cleavage, the resulting mEpEX protein can be
immunoprecipitated from cell culture supernatants with FLAG-
specific antibodies and the greatest part of the protein removed
upon digestion with TEV protease (Figure 2A). The remaining
fragment is small and directly amenable to mass spectrometric
analysis. mEpCAM-TF was stably transfected in HEK293 cells,
mF9 cells, and murine NIH3T3 fibroblasts. Cell culture superna-
tants of each stable transfectant were subjected to FLAG
immunoprecipitation, TEV digestion, and subsequent mass
spectrometric analysis of immunoprecipitates. The resulting
spectra displayed a total of four prominent peaks (Figure 2B) with
determined molecular masses of 4101.70 Da (peak #1),
2218.48 Da (peak #2), 2104.32 Da (peak #3), and 1642.81 Da
(peak #4) (Figure 2C). These four peaks were absent in control
HEK293 cells stably transfected with the pCAG expression vector
and in wild-type, untransfected HEK293 cells (Figure 2B, lower
left panel and data not shown). Each peptide was assigned to
calculated molecular masses and thereby identified at the single
amino acid level (Figure 2C). All four peptides carried a single
positive charge with the exception of peak #1, which also
occurred as a variant with a double positive charge (peak #91).
The double charge of this fragment was confirmed in measure-
ments performed in reflector mode upon the mass differences in
the isotope pattern. Accordingly, peak #91 displayed a halved
mass-over-charge ratio in the mass spectrometry spectra
Figure 1. Cleavage of murine EpCAM in membrane assays. HEK293 cells were stably transfected with full-length mEpCAM in fusion with YFP
(EpCAM-YFP). (A) Schematic representation of cleavage processes resulting in the generation of soluble EpEX, CTF-YFP, and intracellular EpICD-YFP
fragments. (B–C) Membranes of stable transfectants were isolated and either kept at 0uC (0 h) or incubated at 37uC in reaction buffer for the
indicated time points. Thereafter, pellets and supernatant were collected upon differential centrifugation. Pellets (B) and supernatants (C) of
membrane assays were separated in a 10% SDS-PAGE and probed with mEpICD- and YFP-specific antibodies. (D) Embryonic stem cell line E14TG2a
and teratocarcinoma cells mF9 were treated with DMSO (control) or the c-secretase inhibitor DAPT before being subjected to a membrane assay. The
total fraction of the membrane assay was separated in a 10% SDS-PAGE, and probed with a YFP-specific antibody. Treatment with DAPT resulted in
the accumulation of CTF-YFP and in the inhibition of mEpICD-YFP formation. Protein bands corresponding to mEpCAM-YFP, CFT-YFP, and mEpICD-
YFP are indicated in each immunoblot. Shown are the representative results of three independent experiments.
doi:10.1371/journal.pone.0071836.g001
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(Figure 2B). All other masses were additionally recorded in
reflector mode, confirming the data and yielding masses with high
accuracy and small variation to calculated molecular masses (data
not shown). Using MALDI-ToF devices in reflector mode allows
for an increased time of flight of the ion of interest and, hence, for
an improved resolution of spectra and mass accuracy.
Prototype RIP substrates can be cleaved by a-secretases,
typically metalloproteases of the ADAM (A Disintegrin And
Metalloprotease) family and by b-secretase such as BACE1 (Beta-
site APP Cleaving Enzyme 1). In order to assign peptide peaks to
potential proteases, HEK293 cells expressing mEpCAM-TF were
treated with the broadband metalloprotease inhibitor TAPI-1. In
comparison to control-treated cells (DMSO), intensity of peak #4
was decreased by 60% upon TAPI-1 treatment relative to peak #1
(Figure 2D). In contrast, peak #4 became the dominant peak in
spectra of cells treated with the phorbol ester PMA (Figure 2D),
which enhances the activity of ADAM proteases [36]. In parallel,
HEK293 cells expressing mEpCAM-TF were treated with the
BACE1 inhibitor C3 and subjected to mass spectrometric analysis.
Inhibition of BACE1 induced a reduction of peak #1 by more
than 90% relative to peak #4, while transient expression of
BACE1 resulted in a strong increase of peak #1 to become the
dominant peak (Figure 2E). These findings were further substan-
tiated by mass spectrometry measurements in reflector mode.
Thus, mEpCAM is subject to extracellular cleavage by a-secretases
and is a novel substrate of the b-secretase BACE1. Figure 2F
displays a schematic view of the a- and b-secretase cleavage sites in
mEpCAM aligned to corresponding sequences of human Ep-
CAM. The b-secretase cleavage sequence between tyrosine251 and
tyrosine252 was perfectly conserved amongst both proteins, while
the a-secretase sequence between serine230 and lysine231 appeared
to be displaced by one amino acid in the human sequence
(Figure 2F, upper panels). Human and murine EpCAM are
members of the Trop family of proteins comprised of two
specimens, i.e. Trop-1 ( = EpCAM) and Trop-2, which was
recently described to be target of RIP [37]. The b-secretase
cleavage sequence was conserved in both murine family members,
while the a-secretase sequence was not conserved, with a change
of serine230 to an arginine in murine Trop-2 (Figure 2F, lower
panels). A comparative alignment of EpCAM sequences with
cleavage sites in reported ADAM and BACE1 substrates did not
disclose any obvious consensus sequence for cleavage (Table S1).
Determination of Cleavage Sites of g-secretase within
EpCAM
The above mentioned cleavage of mEpCAM by ADAM
protease(s) and BACE1 results in the generation of C-terminal
fragments termed CTF as seen in membrane assays. As shown
above, cleavage of CTF-YFP to mEpICD-YFP was sensitive
towards the treatment of cells with c-secretase inhibitor DAPT (see
Figure 1C). In order to define the cleavage sequences of c-
secretase within mEpCAM at the single amino acid level, a
truncated variant of mEpCAM, which mimics mCTF-YFP, was
generated. Myc-CTF-FT-YFP is comprised of an N-terminal
signal sequence, an N-terminal Myc tag, 15 amino acids of the
extracellular domain, and the transmembrane and intracellular
domain of mEpCAM fused to YFP. Additionally, a FLAG tag and
a TEV recognition site were incorporated C-terminally of the
intracellular domain followed by a short linker region of 6 amino
acids and the YFP moiety (Figure 3A). c-cleavage of Myc-CTF-
FT-YFP would release an Ab-like fragment, which can be
immunoprecipitated from the supernatant with Myc tag-specific
antibodies. e-cleavage of Myc-CTF-FT-YFP would release
mEpICD-TF-YFP, which can be further shortened through
TEV digestion and thereafter immunoprecipitated with FLAG-
specific antibodies (Figure 3A). Myc-CTF-FT-YFP was stably
expressed in HEK293 cells, mF9 cells, and NIH3T3 fibroblasts,
and cell supernatants were used for Myc tag-specific immunopre-
cipitations and mass spectrometric analysis. In all three cell lines,
two major peaks were detected in mass spectrometric spectra,
which were not detectable in HEK293 cells stably transfected with
the pCAG expression vector only of in wild-type untransfected
HEK293 cells (Figure 3B and data not shown). Peak c1
represented an Ab-like peptide of EpCAM after cleavage between
amino acids valine274 and valine275, with a calculated molecular
mass of 3878.49 Da and a detected molecular mass of 3877.11 Da
(Figure 3C). Peak c2 represented an Ab-like peptide of EpCAM
after cleavage between amino acids alanine271 and valine272, with
a calculated molecular mass of 3567.07 Da and a detected
molecular mass of 3563.92 Da (Figure 3C). Treatment of
HEK293 Myc-CTF-FT-YFP cells with the g-secretase inhibitor
DAPT led to a .80% reduction of the intensity of both peaks
(Figure 3D). Note that in Figure 3D and 3F, the ‘‘base peak
relative display’’ function was used in the Data Explorer software
instead of the standard ‘‘display relative’’ mode, in which peaks are
set to 100% and which therefore would preclude a direct
comparison of untreated and treated samples.
In parallel, lysates of stable transfectants of HEK293, mF9, and
NIH3T3 cells were subjected to FLAG immunoprecipitation,
TEV digestion, and elution before mass spectrometric analysis.
Four major peaks were reproducibly detected in spectra of lysates,
with peak e2 representing the major peak. These four peaks were
not detectable in HEK293 cells stably transfected with the pCAG
expression vector only of in wild-type untransfected HEK293 cells
(Figure 3E and data not shown). The first three peaks were aligned
to EpICD molecules generated upon cleavage of EpCAM C-
terminally of valine285, leucine287, and valine288 within the
predicted transmembrane domain (see molecular masses in
Figure 3C; Figure 3G). The fourth peak corresponded to a
cleavage after serine290 within the predicted intracellular domain.
Therefore, we assumed that this cleavage is the result of N-
terminal trimming by intracellular protease(s). The mass difference
of approximately 41,52 Da of peak e29could result from acetyla-
tion (+42 Da) or trimethylation (+42 Da) of lysine residues of the
peptide stretch. Alternatively, this shift could be caused by
addition of a potassium ion (+38 Da). c-Secretase-dependent
generation of the observed peptide peaks was assessed following
treatment of HEK293 transfectants with DAPT. The intensity of
all four major peaks was reduced by .80% (Figure 3F). Alignment
of the corresponding amino acid sequences of murine and human
EpCAM disclosed 100% homology at every c-secretase cleavage
site (c- and e-sites) defined in murine EpCAM (Figure 3G).
Cleavage site c2 and e1–3 were also conserved between murine
EpCAM and murine Trop-2, while cleavage site c1 was changed
from valine to alanine and cleavage site e4 from serine290 to
threonine (Figure 3G).
EpICD is Prone to Degradation by the Proteasome
Cleavage of endogeneous mEpCAM was addressed in mF9 and
E14TG2a cell lines with membrane assays. Since metalloproteases
and BACE1 differ in their pH optimum, membrane assays were
performed at pH7 and pH4. At pH7 and in the absence of any
inhibitor, no mEpCAM fragment was detectable except for full-
length mEpCAM. Inhibition of the c-secretase complex with
DAPT resulted in the accumulation of endogeneous mCTF after
24 h in teratocarcinoma (mF9) and ES cells (E14TG2a) (Figure 4A
and B, left panels). Owing to the abovementioned shedding of
mEpCAM by BACE1, the same experiments were performed at
Cleavage of Murine EpCAM
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pH = 4, which represents the pH optimum of BACE1 [38]. In this
acidic environment, endogeneous mEpCAM was quantitatively
cleaved to generate mCTF, while mEpICD was not detectable
possibly due to the inappropriate pH for the enzymatic activity of
c-secretase and owing to the very small size of the resulting protein
(Figure 4A and B, right panels). Hence, endogeneous mEpCAM is
subject to proteolytic cleavage but detection of mEpICD was
technically not feasible under the assay conditions. Detection of
ICDs generated through presenilin-dependent RIP is usually a
very difficult task due to rapid and efficient degradation of ICDs
after release into the intracellular space [27,28,29]. Detection of
human EpICD was highly inefficient and achieved only upon
immunoprecipitation of large amounts of protein lysate in the
milligram range. This led the authors to the notion that hEpICD is
a very small protein, whose biochemical properties hamper
thorough detection and to the assumption of a potential
degradation of hEpICD through the proteasome [10].
Therefore, we addressed the cleavage and stability of mEpICD
using the mCTF-FT-YFP construct, which is readily processed by
c-secretase, in stable transfectants of HEK293 cells. In line with an
anticipated poor stability of mEpICD, mCTF-YFP was very
weakly and mEpICD-YFP was not detectable in immunoblot
experiments with whole cell lysates of HEK293 and mF9 cells
stably expressing Myc-CTF-FT-YFP in the absence of any
treatment (Figure 5A, DMSO lane). Treatment of cells with the
proteasome inhibitor lactacystin-b-lacton or MG132 strongly
stabilised mEpICD and allowed for the detection of substantial
amounts of cleaved mEpICD (Figure 5A, lanes 4 and data not
shown). Further experiments were conducted with lactacystin-b-
lacton because MG132 was reported to be a pleiotropic drug,
which affects the enzymatic activity of b- and b-secretase to
substantial degree, too [39,40,41]. Interestingly, treatment of cells
with the b-secretase inhibitor DAPT resulted in strong stabilisation
and accumulation of Myc-CTF-FT-YFP, suggesting that primarily
mEpICD and not mCTF is prone to proteasomal degradation
(Figure 5A, lanes 2 and 3). Accordingly, treatment of cells with
lactacystin-b-lacton induced only a minor stabilisation of Myc-
CTF-FT-YFP (Figure 5A, lanes 4). The specificity of all protein
bands was confirmed using lysates from HEK293 cells transfected
with the empty vector only (Figure 5A).
YFP fluorescence was used as a surrogate marker in flow
cytometry experiments for the quantification of Myc-CTF-FT-
YFP derivatives after DAPT and lactacystin-b-lacton treatment.
YFP fluorescence of control-treated cells (DMSO) was set to one
for a comparison. Treatment of cells with the g-secretase inhibitor
DAPT, the proteasome inhibitor lactacystin-b-lacton, or a
combination of both resulted in 4.5-fold, 6.5-fold, and 7.7-fold
increase in YFP fluorescence compared to DMSO, respectively
(Figure 5B). Hence, inhibition of cleavage of Myc-CTF-FT-YFP to
mEpICD-YFP or inhibition of proteasomal activity stabilised YFP
fluorescence to a comparable degree. We concluded from these
results that cleavage of Myc-CTF-FT-YFP to generate mEpICD-
YFP is required for proteasome-dependent degradation.
Mass spectrometric analysis of EpICD disclosed the existence of
variants, which differed in their N-terminal amino acids and in
peak intensities, suggesting differential generation and/or degra-
dation rates (see Figure 3). In order to address a possible
differential degradation of these mEpICD variants, mEpICD
variants from mF9 cells expressing Myc-CTF-FT-YFP were
retrieved from cell lysates or from membrane assays (i.e. in the
absence of cytosolic proteases). mF9 cells were chosen because of
the strong cleavage capacity observed in immunoblot experiments
(See Figure 1C). Mass spectrometric analysis of mEpICD
confirmed the presence of one major variant in mF9 cells
(Figure 5C, upper spectrum, peak e2). Additionally, a second
minor peak termed e1 was detected (Figure 5C). In contrast, five
variants of mEpICD were generated in membrane assays, with
peak e3–5 representing novel components and a substantial
increase in the intensity of peak e1, which became the dominant
peak (Figure 5C, middle panel). A comparable spectrum was
obtained with whole cell lysates of mF9 cells treated with the
proteasome inhibitor lactacystin-b-lacton, confirming a selective
proteasome-mediated degradation of mEpICD variants
(Figure 5C, lower panel). Effects of the inhibition of the
proteasome were recapitulated in HEK293 cells stably expressing
Myc-CTF-FT-YFP with a resulting increase of peak e1 and the
generation of peak e3 and e5 after lactacystin-b-lacton treatment
(Figure 5D). The amino acid sequence of peak e5 was aligned to
calculated molecular mass (Figure 5E) and represents an mEpICD
variant generated upon cleavage after valine286 (Figure 5F).
Comparisons of the amino acid sequences of murine and human
EpCAM and of murine EpCAM and murine Trop-2 in the region
of e-cleavage are shown in Figure 5F. Amino acid sequences were
identical in murine and human EpCAM, while cleavage position
e4 was exchanged from serine to threonine between mEpCAM
and Trop-2 (Figure 5F). Hence, e-cleavage of mEpCAM generates
mEpICD variants, which differ in their N-terminal amino acid
composition and in their sensitivity towards proteasome-mediated
degradation within the cell. Peak e2 corresponded to a mEpICD
variant starting with valine288-isoleucine289 and represented the
most stable mEpICD variant. In order to substantiate these
findings, two versions of soluble mEpICD were cloned, which
contained the N-terminal motifs methionine-valine-leucine-valine-
isoleucine (MVLVI; mimic of peak e1) and methionine-valine-
isoleucine (MVI; mimic of peak e2). MVLVI-EpICD-YFP and
MVI-EpICD-YFP were stably introduced into HEK293 cells and
their respective expression was monitored by flow cytometric
measurement of YFP fluorescence. Treatment of stable transfec-
tants with the proteasome inhibitors lactacystin-b-lacton and
MG132 had only a minor impact on the expression of the MVI-
EpICD-YFP variant, while it strongly increased the expression of
MVLVI-EpICD-YFP (Figure 5G). Quantification of the effects of
inhibitors of the proteasome on the stability of both mEpICD
Figure 2. Determination of the sheddase cleavage amino acid sequence in mEpEX. (A) Schematic representation of mEpCAM-TF
containing a TEV protease recognition site and a Flag-Tag in the mEpEX domain 42 amino acids before the predicted transmembrane domain. After
cleavage by sheddases, the largest part of mEpEX can be removed through digestion with TEV protease and the resulting small fragment
immunoprecipitated using Flag-specific antibodies. (B) Representative mass spectrometry spectrum of HEK293, NIH3T3, and mF9 cells stably
expressing mEpCAM-TF and of vector control HEK293 cells as a control. Four major peak species are indicated. (C) Tabular overview of sheddase
cleavage sites within mEpEX as determined upon mass spectrometric analysis and alignment to potential molecular weights. Calculated and
determined masses are given in Dalton including error and charge of each peptide. (D) Representative mass spectrometry spectrum of HEK293 cells
stably expressing mEpCAM-TF after treatment with DMSO, the metalloprotease protease inhibitor TAPI-1, and the phorbol ester PMA. (E)
Representative mass spectrometry spectrum of HEK293 cells stably expressing mEpCAM-TF after treatment with DMSO, the BACE1 protease inhibitor
C3, and after transient transfection of BACE1 expression plasmid. (F) Sequence alignment of murine and human EpCAM (top), and murine EpCAM
and murine Trop-2 (bottom). metalloprotease protease cleavage (a-secretase) and BACE1 cleavage sites (b-secretase) are indicated.
doi:10.1371/journal.pone.0071836.g002
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variants was conducted with YFP fluorescence values, where
fluorescence of treated cells was set to one. In the absence of
inhibitors, the expression of MVI-EpICD was decreased to 70% of
inhibitor-treated cells, while the expression of MVLVI-EpICD was
reduced to 15% (Figure 5H). Thus, the extended variant of
mEpICD, which included an additional valine and a leucine, was
significantly more prone to proteasomal degradation. According to
the N-end rule, differing N-terminal amino acids regulate the
stability of proteins. However, both EpICD variants display an N-
terminal valine residue and, furthermore, mutation of either
leucine or isoleucine in the second position did not alter the
stability of the resulting EpICD variants (data not shown).
Human EpICD is Prone to Proteasome-dependent
Degradation
In order to specify the cleavage of human EpCAM, membrane
assays were performed with HEK293 cells stably expressing
hEpCAM-YFP. Over time, an accumulation of two C-terminal
fragments of human EpCAM, which preceded the generation of
hEpICD-YFP, was observed (Figure 6A and B). Similarly to
mEpCAM-YFP, the amount of CTF-YFP and hEpICD-YFP in
pellets and soluble fractions of membrane assays were reciprocal,
with hEpICD amounts being highest in the soluble fraction
(Figure 6B). Treatment of stable transfectants of HEK293 cells
with the c-secretase inhibitor DAPT resulted in a loss of hEpICD,
confirming the involvement of c-secretase in the cleavage of CTF-
YFP to hEpICD-YFP (Figure 6C).
In a next step, the stability of cleavage products of CTF-YFP
was addressed in whole cell lysates of HEK293 transfectants and
thus in the presence of intracellular proteases. Barely visible
amounts of hEpICD-YFP were detected in DMSO-treated
transfectants, whereas treatment with DAPT stabilised CTF-YFP
(Figure 6D). Interestingly, treatment of transfectants with the
proteasome inhibitor lactacystin-b-lacton allowed for the visual-
isation of substantial amounts of hEpICD-YFP (Figure 6D). The
fluorescence of YFP was used as a surrogate marker to measure
the expression of CTF-YFP and hEpICD-YFP in dependency of
the treatment of cells with c-secretase and/or proteasome
inhibitor. Inhibition of c-secretase or the proteasone resulted in
a .10-fold and 10-fold increase in YFP fluorescence, respectively
(Figure 6E). Treatment of cells with a combination of both
inhibitors did not result in an additive effect, suggesting that
proteasomal degradation is a major pathway of hEpICD-YFP
destruction (Figure 6E).
Initial reports on the cleavage of human EpCAM primarily
described ADAM17 as sheddase. The finding of BACE1 as a novel
protease involved in cleavage of the extracellular domain of
mEpCAM prompted us to study the cleavage of hEpCAM by
Figure 3. Determination of the c-secretase cleavage amino acid sequence in mEpCAM. (A) Schematic representation of Myc-CTF-YFP
containing an N-terminal c-Myc-tag, a Flag-Tag and a TEV protease recognition site as well as YFP C-terminally of mEpICD. After cleavage by g-
secretase, the Ab-like fragment can be isolated upon immunoprecipitation with c-Myc-specific antibodies. The YFP moiety is removed through
digestion with TEV protease and the resulting small peptide isolated upon immunoprecipitation with Flag-specific antibodies. (B) Representative
mass spectrometry spectrum of HEK293, NIH3T3, and mF9 cells stably expressing Myc-CTF-TF-YFP after immunoprecipitation of supernatants with c-
Myc-specific antibodies. Two major peak species representing g-cleavages are indicated. (C) Tabular overview of c-secretase cleavage sites within
mEpCAM as determined upon mass spectrometric analysis and alignment to potential molecular weights. Calculated and determined masses are
given in Dalton including error of each peptide. (D) Representative mass spectrometry spectrum of HEK293 cells stably expressing mEpCAM-TF after
immunoprecipitation with c-Myc-specific antibodies and treatment with DMSO and the c-secretase inhibitor DAPT. (E) Representative mass
spectrometry spectrum of HEK293, mF9, and NIH3T3 stably expressing Myc-CTF-TF-YFP after TEV digestion and immunoprecipitation with Flag-
specific antibodies. Four major peaks representing e-cleavages are indicated. (F) Representative mass spectrometry spectrum of HEK293 cells stably
expressing mEpCAM-TF after TEV digestion, immunoprecipitation with Flag-specific antibodies, and treatment with DMSO and the c-secretase
inhibitor DAPT. (G) Sequence alignment of murine and human EpCAM (top), and murine EpCAM and murine Trop-2 (bottom). c-Secretase cleavages
at g-position and e-position are indicated.
doi:10.1371/journal.pone.0071836.g003
Figure 4. Cleavage of endogeneous mEpCAM. Proteolytic cleavage of mEpCAM was addressed in mF9 (A) and E14TG2a (B) cells using
membrane assays at pH 7 and pH 4. Membranes of mF9 and E14TG2a cells were incubated for 0 h and 24 h at 37uC and EpCAM fragments were
detected in immunoblots using a mEpICD-specific antibody in combination with an HRP-conjugated secondary antibody. Inhibition of the c-
secretase complex was achieved upon treatment with DAPT where indicated. Shown are the representative results of three independent
experiments.
doi:10.1371/journal.pone.0071836.g004
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Figure 5. Stability of mEpICD species. (A) HEK293 and mF9 cells stably expressing murine Myc-CTF-FT-YFP were treated with DMSO, DAPT,
lactacystin-b-lactone, or DAPT and lactacystin-b-lactone. Protein lysates were separated in a 10% SDS-PAGE and probed with a YFP-specific antibody.
As a control, lysates from vector control HEK293 cells were used (WT). CTF-YFP and EpICD-YFP are annotated. As a loading control, the same
immunoblot membranes were probed with GAPDH-specific antibodies. (B) mF9 cells stably expressing murine Myc-CTF-FT-YFP were treated with
DMSO, DAPT, lactacystin-b-lactone, or DAPT and lactacystin-b-lactone. YFP fluorescence intensities were assessed upon flow cytometry and
normalised to values of DMSO-treated controls. Shown are mean values with standard deviations from three independent experiments. (C) mF9 cells
stably expressing murine Myc-CTF-FT-YFP were subjected to mass spectrometric analysis. To do so, lysates of cells treated with DMSO or the
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BACE1. HEK293 cells stably expressing hEpCAM-YFP were
transiently transfected with either a luciferase or a BACE1
expression plasmid. After 24 hrs, cells were treated with DMSO,
the BACE1 inhibitor C3, DAPT or a combination of C3 and
DAPT. After additional 24 hrs, supernatants were collected and
hEpEX was immunoprecipitated and visualised in immunobloting
using specific antibodies. Expression of BACE1 induced a strong
cleavage of hEpCAM-YFP, which was substantially inhibited upon
treatment with C3 but not DAPT (Figure 6F). As seen in longer
exposures, EpEX shedding in the presence of high-level BACE1
were far superior to those in luciferase-transfected cells (Figure 6F,
lower panel). Levels of BACE1 expression were controlled in
whole cell lysates after transient transfection and disclosed very
high levels of BACE1 (Figure 6F, lower left panel). Hence, human
EpCAM is also a substrate for the BACE1 secretase.
EpCAM is a Conserved Protein Present throughout
Vertebrates
EpCAM was mainly described and characterised in human
[10], mouse [32], rat [42], and zebrafish cells [43]. Here, we
describe the regulated intramembrane proteolysis of the murine
ortholog of EpCAM, which was strongly reminiscent of cleavage
of human EpCAM. We searched for EpCAM orthologs in silico
with the amino acid sequence of human EpCAM as a reference
(NP_002345.2) with the aim to study the conservation of EpCAM
and its cleavage sequences. Combination of blastp and UniProt
searches allowed for the retrieval of 61 partial or complete amino
acid sequences, which could represent putative EpCAM orthologs
in fishes, amphibians, reptiles, birds, a monotreme, marsupials,
ungulates, primates, and rodents. Species’ names, trivial names,
accession numbers, amino acid sequence identity to the human
EpCAM sequence, amino acid conservation, predicted amino acid
counts, and gaps compared to human EpCAM are given in Table
S2 and Figure S1. EpCAM orthologs were not found in plants,
bacteria, viruses, and fungi using available databases. Lowest
sequence identities were found between human EpCAM and
orthologs in fishes (39–46%), while highest sequence identities
were found with orthologs in primates (90–99%) (Table S2). Most
primates contained predicted EpCAM orthologs with amino acid
numbers identical to human EpCAM (314 amino acids), whereas
shorter variants of EpCAM were observed commonly in fishes.
Zebrafish EpCAM is comprised of 302 amino acids and lacks 7
amino acids from the leader peptide and the 5 most C-terminal
amino acids.
In 52 out of 61 sequences of potential orthologs, all exons
encoding the mature EpCAM protein could be identified and were
further considered to study the conservation of EpCAM cleavage
sites (selected species are marked in bold letters in Table S2). It
must be noted that exon 1, which encodes the signal peptide and
part of the first glutamine within the mature protein, was identified
in orthologs using SignalP 4.0 and disclosed from the following
comparison (Figure S1). The conservation of cleavage sites within
EpCAM across the 52 orthologs was assessed using the ClustalW
algorithm with translated proteins sequences. Conservation
coefficients were automatically calculated for each individual
amino acid in the complete sequence and reached a value of 11 in
case of a 100% identity throughout all species. The mean value of
the conservation coefficient (CC) of the complete protein sequence
of EpCAM across all 52 species was 5.86 and, thus, disclosed an
intermediate 53% conservation of EpCAM in all orthologs
(Figure 7). Cleavage sites were analysed in form of six amino
acids from position P23 to P+3 centred on the defined cleavage.
The metalloproteinase cleavage sequence 227FHS*KKM232 in the
extracellular domain of EpCAM (cleavage site *) displayed very
low conservation below the protein average (CC 1–4) (Figure 7A),
whereas the BACE1 cleavage site 249LIY*YVD254 was highly
conserved (Figure 7B). Except for leucine in position P23, all
amino acids in the vicinity of the defined BACE1 cleavage site
were characterised by higher-than-average conservation coeffi-
cient of 9 to 11 and both tyrosines, in between which cleavage
occurs, have a conservation coefficient of 11, representing an
almost perfect conservation throughout all species (Figure 7B).
Cleavage sites of c-secretase, which give rise to mEp-b fragments
(c-cleavage) also displayed very high sequence homology and a
conservation coefficient of 9 to 11 (Figure 7C). In contrast, the
conservation of cleavage sites of c-secretase, which result in the
generation of mEpICD fragments (e-cleavage), was more hetero-
geneous (CC 4–9). Cleavage e2 was slightly more conserved in the
leucine residue (CC 9) and cleavage e4 was less conserved than the
entire amino acid sequence of full-length EpCAM (CC 4–5)
(Figure 7D).
Hence, BACE1 and g-cleavage sites within EpCAM displayed a
great degree of conservation, whereas metalloproteinase and e-
cleavage sites did not.
Discussion
Regulated intramembrane proteolysis of EpCAM was first
described in human carcinoma cells and after ectopic expression in
HEK293 cells [10]. Further indications of a cleavage of human
EpCAM were reported in human embryonic stem cells and in
induced pluripotent stem cells [30,31]. However, cleavage of
orthologs of EpCAM has not been explored and the determination
of precise cleavage sequences has been lacking entirely so far.
Similarly to human EpCAM [10] and other substrates of regulated
intramembrane proteolysis [1], murine EpCAM is subject to
shedding through members of the metalloprotease family (see
Figure 8 for a schematic representation). Additionally, mEpCAM
and hEpCAM are newly identified substrates for the aspartyl
protease BACE1, also termed b-secretase, which is central to the
generation of the pathologic Ab fragment of the amyloid precursor
protein APP in Alzheimer’s disease [44,45,46], and might
therefore also be involved in the production of mEp-b, itself a
proteasome inhibitor lactacystin-b-lactone and lysates from membrane assays were used. Representative mass spectrometry spectrum is depicted
and five major peaks are annotated. Membrane assay probes and treatment with proteasome inhibitor led to the increase of peak e1 and to the
appearance of two peaks e3 and e5. (D) HEK293 cells stably expressing murine Myc-CTF-FT-YFP were treated with DMSO or the proteasome inhibitor
lactacystin-b-lactone. Representative mass spectrometry spectrum is depicted and five major peaks are annotated. (E) Tabular overview of c-
secretase cleavage sites within mEpCAM as determined upon mass spectrometric analysis and alignment to potential molecular weights. Calculated
and determined masses are given in Dalton including error of the peptide. (F) Sequence alignment of murine and human EpCAM (top), and murine
EpCAM and murine Trop-2 (bottom). c-Secretase cleavages at e-position are indicated. Solid triangle marks the cleavage site of the stable EpICD
variant, grey triangles cleavage sites of labile EpICD variants, and open triangle of N-terminally trimmed EpICD. (G) HEK293 cells stably expressing
murine MVI-EpICD-YFP and MVLVI-EpICD-YFP mutants were subjected to flow cytometry assessment of YFP fluorescence. Shown are representative
graphs of both stable transfectants after treatment with DMSO or lactacystin-b-lactone. (H) YFP fluorescence intensities of HEK293 transfectants
stably expressing murine MVI-EpICD-YFP and MVLVI-EpICD-YFP mutants are given as mean fluorescence intensity ratios. Cells treated with
lactacystin-b-lactone served as reference and values were set to one for comparison.
doi:10.1371/journal.pone.0071836.g005
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Figure 6. Cleavage and proteasomal degradation of human EpCAM. HEK293 cells were stably transfected with hEpCAM-YFP and used to
determine cleavage products of hEpCAM in membrane assays. Membranes of stable transfectants were isolated and either kept at 0uC (0 h) or
incubated at 37uC in reaction buffer for the indicated time points. Thereafter, pellets and supernatant were collected upon differential centrifugation.
Pellets (A) and supernatants (B) of membrane assays were separated in a 10% SDS-PAGE and probed with hEpICD- and YFP-specific antibodies. (C)
HEK293 hEpCAM-YFP transfectants were treated with DMSO (control) or the c-secretase inhibitor DAPT before being subjected to a membrane assay.
The total fraction of the membrane assay was separated in a 10% SDS-PAGE, and probed with a YFP-specific antibody. Treatment with DAPT resulted
in the accumulation of CTF-YFP and in the inhibition of hEpICD-YFP formation. (D) HEK293 human Myc-CTF-TF-YFP transfectants were treated with
DMSO (control), the c-secretase inhibitor DAPT, the proteasome inhibitor b-lacto-lactocystin (b-Lac), or combination of both. Thereafter, whole cell
lysates were separated in a 10% SDS-PAGE, and probed with a YFP-specific antibody. Treatment with b-lacto-lactocystin resulted in an accumulation
of hEpICD-YFP. Similar loading of protein lysates was visualised upon staining of tubulin on the same blots. Protein bands corresponding to human
Myc-CTF-TF-YFP and mEpICD-YFP are indicated in each immunoblot. Shown are the representative results of three independent experiments. (E) YFP
fluorescence was analysed in dependency of the treatment of HEK293 human Myc-CTF-TF-YFP transfectants. DMSO treatment served as a reference
and values were normalised to one. Shown are the mean values with standard deviations from three independent experiments. (F) HEK293 cells
stably expressing hEpCAM-YFP were transiently transfected with expression plasmids for luciferase (Luc) as a control or BACE1 (BACE1). After 24
hours, supernatants were removed and cells treated with the indicated inhibitors of BACE1 (C3), c-secretase (DAPT) or combinations thereof. After
additional 24 hours, supernatants were collected and hEpEX was immunoprecipitated and visualised upon immunoblotting with specific antibodies.
Shown are two representative results with exposure times (1 s and 10 s). Over-expression of BACE1 and equal protein loading were verified upon
immunobloting (lower left and right panel, respectively).
doi:10.1371/journal.pone.0071836.g006
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newly defined fragment of EpCAM (Figure 8). Despite a reported
expression of BACE1 primarily in brain, hypothalamus, spinal
cord, and pancreas [47], mRNA transcripts were detected in all
cell lines used in the present study, with highest levels present in
embryonic stem cells (data not shown). Fostered expression of
BACE1 resulted in increased cleavage of both, human and murine
EpCAM, and corroborated the results of treatments with small
molecule inhibitors of BACE1. The intensity of cleavage of
EpCAM through BACE1 was cell line-dependent and appeared
most prominent in HEK293 cells, whereas it was minor in
teratocarcinoma cells, where major cleavage of EpEX was
essentially metalloprotease-dependent. In contrast, in fibroblasts
an additional and yet to be characterised protease seems to have a
major contribution to EpCAM shedding (see Figure 2B, NIH3T3
cells). Since BACE1 is active under acidic conditions and deploys
its activity at a pH optimum of pH 4–4.5 [38], and primarily in
endosomes and the trans-Golgi network [48], it is conceivable that
differences in BACE1-dependent cleavage of EpCAM are related
to differential targeting of EpCAM to endosomes.
Congenital tufting enteropathy (CTE) is a severe paediatric
disease caused by a point mutation of EpCAM (Cys66Tyr). This
mutant of EpCAM interferes with the proper localization into the
cell membrane in several ways and eventually results in a lack of
plasma membrane-associated EpCAM [49,50]. However, the
EpCAM (Cys66Tyr) mutant is still cleaved and is able to generate
EpCAM-derived CTFs [49,50]. Accordingly, it was speculated
that EpCAM might be cleaved in the Golgi apparatus or in the ER
lumen. Our data support the idea of a cleavage of EpCAM
independently of its localisation at the plasma membrane and
suggest cleavage to occur in intracellular compartments such as
endosomes and lysosomes. It is tempting to speculate that BACE1
fulfils the cleavage of EpCAM (Cys66Tyr) mutant in CTE and
might partially compensate for the missing EpICD generation at
the cell membrane or prevent accumulation of the EpCAM
(Cys66Tyr) mutant in endosomes. As deduced from cleavage assays
performed at different pH values, cleavage of mEpCAM at the
plasma membrane (pH 7) appears far less efficient than in acidified
intracellular organelles (pH4). From this, we suggest that only a
proportion of EpCAM molecules are cleaved at the plasma
membrane, whereas EpCAM is cleaved to nearly 100% once
internalised in endosomes. Quantitative cleavage of mEpCAM in
the trans-Golgi network on its way to the plasma membrane
appears implausible since mEpCAM can be detected at the plasma
membrane to high levels with antibodies binding within the
ectodomain. Anyhow, it appears that metalloproteases and
BACE1 are the major sheddases involved in regulated intramem-
brane proteolysis of EpCAM, although we cannot rule out that
other proteases might play important roles in the shedding of
murine EpCAM.
We determined several cleavage sites within the intramembrane
domain of mEpCAM, which gave rise to newly identified Ab-like
fragments now termed mEp-b and mEpICD variants (Figure 8).
The existence of Ab-like fragments of mEpCAM is described for
the first time in the present study and might add up to a potential
role for this part of the protein, possibly in conjunction with the
cleavage through BACE1, as was extensively described for APP in
Alzheimer’s disease [46]. Gelatinous drop-like corneal dystrophy
(GDLD) is an autosomal recessive disorder characterized by
corneal amyloidosis leading to blindness. GDLD is associated with
mutations in the EpCAM paralog Trop2, also known as
TACSTD2 [51], which was most probably generated through
retroposition of the EpCAM transcript [52]. Although speculative
in nature, it is conceivable that regulated intramembrane
proteolysis of Trop2, which was described recently in detail [37],
results in the generation of Ab-like fragments similarly to EpCAM
and contributes to corneal amyloidosis. Described mutations in
Figure 7. Sequence conservation of cleavage sites in orthologs
of EpCAM found in fishes, amphibians, birds, to placental
mammals. Amino acid sequences of 52 orthologs of human EpCAM
were aligned using ClustallW and sequence conservation of each amino
acid was calculated (maximum score 11. Shown are the mean
conservation score throughout all orthologs (mean) and conservation
scores of single amino acids ranging positions p23 to p+3 around
determined cleavage sites of metalloproteases (A), BACE1 (B), c-
cleavage of c-secretase (C), and e-cleavage of c-secretase (D).
doi:10.1371/journal.pone.0071836.g007
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GDLD are located away from potential cleavage sites within
Trop2, however, these changes in the amino acid composition
might impact on the overall structure and, thus, indirectly on
processing of the protein. Owing to two different c-cleavage sites
and to leastwise one a- and one b-cleavage site, a combinatorial of
four different Ab-like fragments of EpCAM can be envisaged. A
potential role for mEp-b fragments from EpCAM is so far unclear
and subject to further studies.
Out of the five different mEpICDs variants determined in the
present study, only one fragment was stable enough to be detected
at decent levels in mass spectrometry of untreated cells and might
represent the mEpICD protein detected to low amounts in
immunoblot experiments. This mEpICD molecule displayed an
N-terminal region composed of valine and isoleucine, while an
mEpICD fragment with the amino acids valine and leucine added
to its N-terminus displayed greatly diminished stability. Since the
first amino acid at the N-termini of both EpICD variants were
identical (valine), differences in stability can hardly be explained
according to the N-end rule. Furthermore, mutation of either the
leucine or the isoleucine in second position of the mEpICD
variants did not significantly alter stability (data not shown).
Interestingly, both mEpICD fragments were generated in similar
amounts at the plasma membrane as demonstrated in membrane-
based assays. The observed decreased expression of the longer
mEpICD species in lysates was was dependent upon the
proteasome. Furthermore, inhibition of c-secretase induced an
accumulation of the murine and human CTF fragments of
EpCAM, which were only marginally increased upon further
treatment with proteasome inhibitors and which might be the
result of endoplasmatic-reticulum-associated protein degradation
(ERAD) [53]. Based on these findings and on the fact that
treatments with c-secretase and proteasome inhibitors were not
additive, we conclude that EpICDs but not CTFs are subject to
differential proteasomal degradation. Ectopically expressed vari-
ants of mEpICD, which mimic endogeneous EpICDs, confirmed
these assumptions. Differential stability of intracellular domains
was similarly demonstrated for the case of Notch [54]. Here,
stability of Notch-ICD impacted on the signalling capacity of the
Notch receptor with a substantial silencing through degradation.
Furthermore, endocytosis was implicated in the regulation of the
generation of differing Notch-ICD variants. Together with the fact
that BACE1 is active in the acidic milieu of endosomes [38], it is
Figure 8. Schematic representation of EpCAM presenilin-dependent regulated intramembrane proteolysis (PS-RIP) and
endocytosis. Murine EpCAM (mEpCAM) is cleaved at the plasma membrane to release soluble EpEX (smEpEX). The resulting C-terminal fragment
(mCTF) is a substrate for c-secretase, which cleaves mCTF to generate soluble, extracellular mEp-b fragments (c-cleavage) and intracellular mEpICD
fragments, which are prone to proteasomal degradation. Additionally, mEpICD can be endocytosed and processed either by BACE1 in acidic
intracellular compartments (endosome) and/or by acidic hydrolases in lysosomes.
doi:10.1371/journal.pone.0071836.g008
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tempting to speculate that BACE1-mediated cleavage of EpCAM
in endosomes results in the formation of mEpCID molecules with
differing stability and contributes to the regulation of the overall
amount of EpCAM in cells in a very efficient manner. It must
however be noted that the overall stability of murine EpICD
variants was anyhow very low and proteasomal degradation of
mEpICD very potent. Human EpCAM is a rather stable protein
with a half-life of 21 hours at the plasma membrane [55].
However, in certain conditions rapid down-regulation of EpCAM
might appear necessary, for example in cells undergoing
differentiation such as tissue progenitors and embryonic stem
cells, in which rapid and efficient fine-tuning of EpCAM
expression might be of paramount importance [30,32,56]. In
such situations, regulated intramembrane proteolysis, which
induces a quantitative degradation of EpCAM (via EpICD
degradation), might support or even precede effects at the
transcriptional levels.
In homology to murine EpCAM, we have confirmed the
existence of C-terminal fragments of human EpCAM and
demonstrated a comparable sensitivity of hEpICD towards
proteasomal degradation, which corroborated the effective degra-
dation of hEpICD first mentioned in 2009 [10]. The existence of
human CTF, whose generation precedes that of hEpICD, is in
accordance with the findings by Schnell et al., who reported on the
existence of hEpCAM CTFs of 20 kD and ranging from 12 to
15 kD [49]. Although we could not confirm the presence of a
20 kD CTF at all time points of cleavage, human and murine
CTFs ranging from 12 to 15 kD were detected in HEK293 cells,
and murine CTFs were described at the single amino acid levels
using mass spectrometry approaches. A mimic of hCTF, which
lacked biggest parts of the extracellular domain of wildtype
hEpCAM, was quantitatively processed to hEpICD and thus far
more efficiently cleaved by the c-secretase complex than wild-type
hEpCAM. Hence, the initial shedding of human and murine
EpCAM represents the rate-limiting step in the cleavage of the
protein and most probably dictates cleavage levels as seen at the
plasma membrane.
Lastly, the conservation of cleavage sites, and thus the potential
importance of EpCAM cleavage, was addressed in newly identified
orthologs of the protein. Sequences corresponding to the full-
length protein or parts of EpCAM were identified in a total of 61
different species ranging from fishes, amphibians, birds, to
placental mammals. Fifty-two orthologs could be assigned
unequivocally and were considered in the comparative study.
Eventually, BACE1 and the c-cleavage site displayed a very high
degree of conservation throughout all orthologs, whereas metallo-
protease and e-cleavage sites displayed very low and an
intermediate conservation, respectively. This very high degree of
conservation in BACE1 and g-cleavage sites were also seen in
incomplete sequences of the most distant ortholog in the lamprey,
a jawless fish of a very ancient lineage of vertebrates. Since BACE1
and the c-cleavage site have been conserved to such a high degree,
it is imaginable that the generation of mEp-b fragments is of major
importance for the function of EpCAM throughout evolution.
In summary, we present a comprehensive overview of cleavage
processes associated with the tumour and stem cell associated
receptor EpCAM at the single amino acid level. Novel aspects
relate to the shedding of EpCAM through BACE1 most probably
after endocytosis of the molecule, the generation of Ab-like
fragments, and the existence of various mEpCID molecules that
are efficiently but differentially degraded via the proteasome
(Figure 8). According to similarities at the amino acid level, these
features might be shared by orthologs of EpCAM and Trop2
proteins in numerous vertebrates and therefore might represent a
general theme of regulation of EpCAM.
Materials and Methods
Cell Lines
E14TG2a embryonic stem cells [57] were a kind gift from Dr.
Marcus Conrad (Munich) cultured in Stempan Gmem medium
(PAN-Biotech, Aidenbach, Germany) and leukemia inhibitory
factor (LIF, 1,000 U/ml; Merck KGaA, Darmstadt, Germany) on
0.1% gelatin-coated 6-well plates. Murine F9 teratoma (kind gift
from Dr. Marcus Conrad, Munich) cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, high glucose)
supplemented with 20% FCS (Biochrom AG, Heidelberg,
Germany) and 1% penicillin/streptomycin. Human embryonic
kidney 293 cells (HEK293) and NIH3T3 fibroblasts were cultured
in DMEM supplemented with 10% FCS and 1% penicillin/
streptomycin. All cell lines were grown in a 5% CO2 atmosphere
at 37uC.
Transfections and Expression Vectors
Transfections were performed with the MATra reagent (Iba,
Goettingen, Germany) following the manufacturer’s recommen-
dations. Alternatively, embryonic stem cells were transfected with
the Amaxa Nucleofector system and the Mouse ES Cell
Nucleofector Kit (Lonza, Ratingen, Germany). EpCAM full-
length (314 aa) was cloned in fusion with a YFP-Tag to generate
EpCAM-YFP. The EpCAM-TF construct was cloned by the
introduction of a TEV-cleavage site (ENLYFQG) followed by a
FLAG-tag (DYKDDDDK) between amino acid 223 and 224 of
EpCAM. Myc-CTF-FT-YFP consists of the signal peptide of
murine EpCAM (1–23), a short linker peptide consisting of two
amino acids (KL), a Myc-Tag (EQKLISEEDLYVDEKA-
PEFSMQGLT), the CTF sequence of murine EpCAM (251–
315), a Flag-Tag (DYKDDDDK), and the TEV recognition site
(ENLYFQG) followed by a YFP-Tag. Expression vectors for the
EpICD mutants MVLVI-EpICD-YFP (251 to 315 aa) and MVI-
EpICD-YFP (253 to 315 aa) are N-terminal truncated versions of
the cMyc-CTF-FT-YFP construct. All constructs mentioned above
were cloned into the 141 pCAG-3SIP expression vector by using
EcoRI and NheI restriction enzyme sites. Stable selection of
transfectants was performed with puromycin (4 ng/ml) in the
according culture medium starting at one day after transfection.
The pcDNA3.1 plasmid was used for BACE1 over-expression. For
determination of the a- and b-cleavage sites transient BACE1
over-expression was performed 24 h before the medium was
changed.
Membrane-based EpCAM Cleavage Assay
These assays were performed as described earlier [34].
Protein Analysis
For immunobloting, cells were lysed in PBS containing 1% n-
dodecyl b-D-maltoside (Sigma, Munich, Germany) and protease
inhibitors (Roche complete, Roche, Grenzach, Germany). Protein
concentrations were determined using the BCA-assay (Thermo
Scientific, Erlangen, Germany). Equal amounts of proteins were
separated by SDS-PAGE (10–15%) and visualized using antibod-
ies against mEpICD (immunising peptide:TRKKSAKYEKAEI-
KEMGEIHRELNA,Charles River, Cologne, Germany), hEpICD
and YFP (anti-GFP antibodies bind specifically to YFP; Santa
Cruz, Heidelberg, Germany) in combination with horseradish
peroxidase (HRP)-conjugated secondary antibodies, and the ECL
reagent (Millipore, Darmstadt, Germany). Bioluminescence was
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assessed in a Chemidoc XRS+ imaging system (Bio-Rad, Munich,
Germany).
Proteomics and Mass Spectrometry
a- and b-cleavage sites. After cells were grown to con-
fluency, medium was changed and collected after 24 h for Flag
IPs. Supernatants from NIH3T3 and HEK293 cell lines (15 ml)
and mF9 cell line (50 ml) were used for the Flag immunoprecip-
itation with 30 ml of Flag beads (M2 Sigma, Munich, Germany)
over night at 4uC on a rotating device. Beads were washed 3 times
with PBS and twice with water. Proteins were eluted with 40 ml
glycine (100 mM; pH 2,5) on ice for 15 min. Eluted peptides were
transferred to a new vial and neutralized by addition of 200 ml Tris
(100 mM; pH 8). Overnight digestion with TEV protease
(Invitrogen, Cologne, Germany) was performed following the
manufacturer’s recommendations. Flag-Tag containing peptides
were immunoprecipitated with 10 ml Flag-beads at 4uC for 4 hours
in a rotating device. After washing of beads 3 times with PBS and
twice with water, peptides were eluted in 10 ml acetonitrile (Sigma,
Munich, Germany) and water (1:1) saturated with a-cyano-4-
hydroxyl-cinnamic acid (Sigma, Munich, Germany), and subse-
quently analysed in a Voyager-DE STR mass spectrometer
(Applied Biosystems, Cologne, Germany).
c-cleavage sites. After cells were grown to confluency, the
medium was changed and collected after 24 h for Myc-immuno-
precipitation. For this immunoprecipitation, 50 ml of cell culture
supernatant and 15 ml of Myc-beads (Sigma, Munich, Germany)
were mixed overnight in a rotator device at 4uC. The washing
steps and peptide elution were performed as described above.
e-cleavage sites. Immunoprecipitation was performed with
the YFP-Trap system (Chromotek, Munich, Germany) using
4000 mg protein lysate in combination with 30 ml YFP-Trap at
4uC for 4 h in a rotating device. All following steps were
performed as described above.
Cells stably expressing cMyc-CTF-FT-YFP used for membrane
isolation were treated for 24 h with DAPT with the concentration
of 1 mM (Sigma, Munich, Germany).
Inhibitors
Inhibition of a-, b- and c-secretase was performed using TAPI-1
(50 mM, Merck-Millipore, Darmstadt, Germany), C3 (1 mM,
Merck-Millipore, Darmstadt, Germany), and DAPT (1 mM,
Sigma, Munich, Germany) respectively. Inhibitors were supple-
mented when medium was changed. Phorbol ester phorbol-12-
myristate-13-acetate (Sigma, Munich, Germany) was substituted in
a concentration of 1 mM, 2 h before the cell culture supernatant
was collected. Treatment with lactacystin b-lactone (Santa Cruz,
Heidelberg, Germany) with a concentration of 50 mM was
performed for 12 h. MG132 (Merck-Millipore, Darmstadt,
Germany) was supplemented 4 h before cells were harvested into
the medium with a final concentration of 10 mM.
Flow Cytometry
YFP expression of cells was analysed in a FACScalibur
cytometer (Becton Dickinson). FACS buffer contained 3% of
FCS in PBS. Living cells were gated according the forward (FSC)
and side scatter (SSC).
RNA Isolation, cDNA Synthesis and Quantitative Real-
time Polymerase Chain Reaction
RNeasy Plus Universal Kit (Qiagen, Hilden, Germany) was
used for RNA isolation. For cDNA synthesis, QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany) was used. The
QuantiTect SYBR Green PCR Kit (Qiagen, Hilden, Germany)
was used for the measurement in a light cycler 480 (Roche,
Mannheim, Germany).
Immunoprecipitation of hEpEX
Immunoprecipitation of hEpEX was performed as described
earlier [10].
Identifications of EpCAM Orthologs in different Species
and Alignment of Corresponding Sequences
Various amino acid sequences from orthologs of EpCAM were
retrieved from available databases in NCBI blastp and UniProt
with the amino acid sequence of human EpCAM (NP_002345.2)
as bait. Additional EpCAM sequences could be identified by
BLASTN using all exon sequences of human EpCAM for the
search in the Ensembl database. The software Jalview and the
ClustalW Multiple Sequence Alignment algorithm were used for
alignments and calculation of conservation values.
Supporting Information
Figure S1 Sequence alignment of EpCAM amino acids
including localisation of the predicted transmembrane
domain (TMD), a, b, c, and e cleavage sites.
(DOCX)
Table S1 Comparison of ADAM and BACE1 cleavage
sites in described substrates. m: murine; h: human, aa:
amino acids.
(DOCX)
Table S2 Vertebrate EpCAM amino acid sequence
comparisons with the Homo sapiens EpCAM sequence.
Latin species names (bold, full length sequences of mature
EpCAM proteins available), abbreviations used, common names,
accession numbers with hyperlink, amino acid identities, similar
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